Potential Role of Plasma Myeloperoxidase Level in Predicting Long-Term Outcome of Acute Myocardial Infarction
| Autor: | Kaya, Mehmet Gungor, Yalcin, Ridvan, Okyay, Kaan, Poyraz, Fatih, NILÜFER BAYRAKTAR, Pasaoglu, Hatice, Boyaci, Bulent, Cengel, Atiye |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Time Factors Turkey Myocardial Infarction Kaplan-Meier Estimate Patient Readmission Risk Assessment Angina Pectoris Young Adult Recurrence Risk Factors Myocardial Revascularization Odds Ratio Humans Clinical Investigation Prospective Studies cardiovascular diseases Aged Peroxidase Proportional Hazards Models Aged 80 and over Heart Failure Chi-Square Distribution Incidence Middle Aged Prognosis Up-Regulation Case-Control Studies Multivariate Analysis Female Biomarkers |
| Zdroj: | Europe PubMed Central Publons Scopus-Elsevier ResearcherID |
| Popis: | We investigated the prognostic importance of plasma myeloperoxidase levels in patients with ST-elevation myocardial infarction (STEMI) at long-term follow-up, and we analyzed the correlations between plasma myeloperoxidase levels and other biochemical values. We evaluated 73 consecutive patients (56 men; mean age, 56 ± 11 yr) diagnosed with acute STEMI and 46 age- and sex-matched healthy control participants. Patients were divided into 2 groups according to the median myeloperoxidase level (Group 1: plasma myeloperoxidase ≤ 68 ng/mL; and Group 2: plasma myeloperoxidase68 ng/mL). Patients were monitored for the occurrence of major adverse cardiovascular events (MACE), which were defined as cardiac death; reinfarction; new hospital admission for angina; heart failure; and revascularization procedures. The mean follow-up period was 25 ± 16 months. Plasma myeloperoxidase levels were higher in STEMI patients than in control participants (82 ± 34 vs 20 ± 12 ng/mL; P = 0.001). Composite MACE occurred in 12 patients with high myeloperoxidase levels (33%) and in 4 patients with low myeloperoxidase levels (11%) (P = 0.02). The incidences of nonfatal recurrent myocardial infarction and verified cardiac death were higher in the high-myeloperoxidase group. In multivariate analysis, high plasma myeloperoxidase levels were independent predictors of MACE (odds ratio = 3.843;95% confidence interval, 1.625-6.563; P = 0.003). High plasma myeloperoxidase levels identify patients with a worse prognosis after acute STEMI at 2-year follow-up. Evaluation of plasma myeloperoxidase levels might be useful in determining patients at high risk of death and MACE who can benefit from further aggressive treatment and closer follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|